Compare · ABBV vs ELAN
ABBV vs ELAN
Side-by-side comparison of AbbVie Inc. (ABBV) and Elanco Animal Health Incorporated (ELAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ELAN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $500.80B, about 42.6x ELAN ($11.76B).
- ABBV has been more active in the news (16 items in the past 4 weeks vs 5 for ELAN).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- Elanco Animal Health Incorporated
- Price
- $285.46+0.75%
- $23.56+0.13%
- Market cap
- $500.80B
- $11.76B
- 1M return
- -
- +3.61%
- 1Y return
- -
- +8.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2012
- 2018
- News (4w)
- 16
- 5
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Latest ABBV
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- SEC Form 8-K filed by AbbVie Inc.
- AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- SEC Form 8-K filed by AbbVie Inc.
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
- AbbVie to Host Third-Quarter 2026 Earnings Conference Call
Latest ELAN
- Goldman initiated coverage on Elanco Animal Health with a new price target
- SEC Form 4 filed by Elanco Animal Health Incorporated
- SEC Form 4 filed by Elanco Animal Health Incorporated
- SEC Form 4 filed by Elanco Animal Health Incorporated
- SEC Form 4 filed by Director Anand Kapila K
- SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N
- SEC Form 4 filed by Officer Modi Rajeev A.
- SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M
- Elanco to Participate in BofA Securities Global Healthcare Conference 2026
- Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care